Companies ›Healthcare ›CRBP

CRBP — Nasdaq Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc.

$8,92

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

166,9M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

-18,2 %

Net margin

—

Debt / equity

0,13

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$9,00

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for inflammatory and autoimmune diseases, primarily generating capital through equity offerings and licensing agreements rather than product revenue.

Business. Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification78 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership→

BlackRock Institutional Trust Company, N.A.

largest disclosed fund holder

Profitability→

-18,2 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning CRBP.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to CRBP. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification78 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

AI synthesis

GENERATED

Corbus Pharmaceuticals maintains a debt-light capital structure with $15.9 million in short-term debt and no long-term debt, resulting in a low debt-to-equity ratio of 0.13. The company holds $25.7 million in cash and equivalents against total liabilities of $18.1 million, yielding a robust current ratio of 7.92. Despite this liquidity buffer, the firm faces significant cash burn, with operating cash flow at -$25.6 million and free cash flow at -$25.6 million for the quarter. The market capitalization stands at $168.4 million, trading at 1.33x price-to-book, while negative earnings metrics render EV/EBITDA and P/E ratios non-operational for traditional valuation.

Profitability remains deeply negative, with a net income of -$22.97 million and operating income of -$24.3 million for Q1 2026. Return on equity is -18.18% and return on assets is -15.9%, reflecting the pre-revenue nature of the business. Without revenue data to compare against cohort medians, the company’s economic model relies entirely on capital preservation and future clinical milestones rather than current margin generation. The absence of positive earnings precludes standard profitability comparisons, highlighting the speculative nature of the investment thesis.

Key takeaways

High dilution risk driven by recent equity offerings and an active ATM agreement allowing up to $150 million in sales.
Strong liquidity position with a 7.92 current ratio, but offset by significant negative operating cash flow of -$25.6 million.
Going-concern language in filings highlights substantial doubt about long-term viability without additional capital or revenue.
No long-term debt and low debt-to-equity ratio of 0.13 provide a clean balance sheet but limited leverage for growth.
Strategic partnership with CSPC and Australian subsidiary indicate international development focus, though revenue impact is not yet realized.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-31

Q4 2025 · Quarter highlights

Operating income -$24.3M.

Revenue—

Operating income-$24.3M

Net income-$23.0M

Free cash flow-$25.6M

EPS—

Operating cash flow-$25.6M

Financials

Income statement

Revenue—

Gross profit—

Operating income-$24.3M

Net income-$23.0M

Balance sheet

Total assets$144.5M

Total liabilities$18.1M

Total equity$126.3M

Cash & equivalents$25.7M

Long-term debt—

Cash flow

Operating cash flow-$25.6M

CapEx$6.0k

Free cash flow-$25.6M

SBC$1.9M

Highlights

▍Operating income -$24.3M

Valuation FY

Market price

$8,92

Market cap

$168.4M

Enterprise valueⓘ

$46.0M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

1.3x

P / Tangible bookⓘ

1.3x

Tangible book

$126.3M

Net cashⓘ

$122.3M

Current ratioⓘ

7.9

Debt / equityⓘ

0.1

ROAⓘ

-15.9%

ROEⓘ

-18.2%

Cash conversionⓘ

111.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

5.5%

Revenue by segment

Business relationships

Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures

Partners1

Cspc Pharmaceutical Group Lt1093.HKPartner95%

Supply chain

Vendors → CRBP ↔ Partners → Customers · click any node to drill

0 mentions in 10-K0 from corporate websites0 from news dispatches

Updated 2026-07-07

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution10 analysts

Strong buy5

Buy5

Hold0

Sell0

Strong sell0

12-month price target$41,67 · Median $40,00

Low $28,00High $57,00

Operating income · consensus-93,9M USD

EPS surprise

−31,7 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$28,00

Mean$41,67

Median$40,00

High$57,00

Spot$8,92

+367.1 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskHigh

Liquidity riskHigh

Filing-based flags

Diluted share count is moderately above the basic share count.
Filings reference going-concern or substantial-doubt language.
Source documents mention dilution or offering risk.

Benchmarks vs cohort

ROE-18,2 %Bottom quartile

D/E0,13Above median

Cash Conv1,11Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 655 304 sh2 exercises · 11 grants11 insiders

Saxena Nishant CChief Business Officer · Stock options (right to buy) → Common StockAcquired 192 300 @ $11,51grant · 2026-05-21
Ben YongDirector · Stock options (right to buy) → Common StockAcquired 12 300 @ $9,15grant · 2026-05-19
Kung WinstonDirector · Stock options (right to buy) → Common StockAcquired 12 300 @ $9,15grant · 2026-05-19
Jacques Rachelle SuzanneDirector · Stock options (right to buy) → Common StockAcquired 12 300 @ $9,15grant · 2026-05-19
Jenkins John KennethDirector · Stock options (right to buy) → Common StockAcquired 12 300 @ $9,15grant · 2026-05-19
Altmeyer AnneDirector · Stock options (right to buy) → Common StockAcquired 12 300 @ $9,15grant · 2026-05-19
Pfeiffenberger BrentDirector · Stock options (right to buy) → Common StockAcquired 24 700 @ $9,15grant · 2026-05-19
Cohen YuvalDirector, Chief Executive Officer · Stock options (right to buy) → Common StockAcquired 150 000 @ $8,26grant · 2026-01-14
Smethurst DominicChief Medical Officer · Stock options (right to buy) → Common StockAcquired 85 095 @ $8,26grant · 2026-01-14
Moran Sean F.Chief Financial Officer · Stock options (right to buy) → Common StockAcquired 84 247 @ $8,26grant · 2026-01-14
Hodgson IanChief Operating Officer · Stock options (right to buy) → Common StockAcquired 85 095 @ $8,26grant · 2026-01-14
Cohen YuvalDirector, Chief Executive Officer · Stock options (right to buy) → Common StockDisposed 8 973 @ $4,26exercise · 2025-10-27
Cohen YuvalDirector, Chief Executive Officer · Stock options (right to buy) → Common StockDisposed 18 660 @ $4,26exercise · 2025-10-24

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Cash Conversion Ratio
operating_cash_flow / net_income
Market Price
input from market-data provider (delayed close or quote-shim mid)
Enterprise Value
market_cap - net_cash
Return On Assets
net_income / total_assets
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic

Source documents

Corbus Pharmaceuticals Holdings, Inc. company facts · 2026-07-07
Corbus Pharmaceuticals Holdings, Inc. 10-Q 2026-05-12 · 2026-07-07
Corbus Pharmaceuticals Holdings, Inc. 10-K 2026-03-09 · 2026-07-07
Corbus Pharmaceuticals Holdings, Inc. 10-Q 2025-11-12 · 2026-07-07
Corbus Pharmaceuticals Holdings, Inc. 10-Q 2025-08-05 · 2026-07-07
8-K (sec_8k_material) on CRBP · 2026-07-07
Corbus Pharmaceuticals Holdings, Inc. HA canonical relationships · 2026-07-07

Ownership & reference

Top holders

BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$34M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$1M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$1M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$2M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$7M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$0M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$1M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M

Insider activity

Net selling2 buys · 12 sellsnet -$1,0M12 insiders · last 365d

Altmeyer AnneDirector · Common Stock, par value $0.0001 per shareSold 2 412 @ $7,91$19K · 2026-06-10
Jenkins John KennethDirector · Common Stock, par value $0.0001 per shareSold 4 800 @ $7,91$38K · 2026-06-10
Kung WinstonDirector · Common Stock, par value $0.0001 per shareSold 2 026 @ $7,91$16K · 2026-06-10
Saxena Nishant CChief Business Officer · Common Stock, par value $0.0001 per shareBought 9 000 @ $7,58$68K · 2026-06-03
Saxena Nishant CChief Business Officer · Common Stock, par value $0.0001 per shareBought 4 500 @ $7,33$33K · 2026-06-02
Saxena Nishant CChief Business Officer · Common Stock, par value $0.0001 per shareOther 58 300 · 2026-05-21
Jacques Rachelle SuzanneDirector · Common Stock, par value $0.0001 per shareOther 3 800 · 2026-05-19
Kung WinstonDirector · Common Stock, par value $0.0001 per shareOther 3 800 · 2026-05-19
Jenkins John KennethDirector · Common Stock, par value $0.0001 per shareOther 3 800 · 2026-05-19
Altmeyer AnneDirector · Common Stock, par value $0.0001 per shareOther 3 800 · 2026-05-19
Ben YongDirector · Common Stock, par value $0.0001 per shareOther 3 800 · 2026-05-19
Pfeiffenberger BrentDirector · Common Stock, par value $0.0001 per shareOther 7 500 · 2026-05-19
Smethurst DominicChief Medical Officer · Common Stock, par value $0.0001 per shareSold 6 097 @ $8,30$51K · 2026-03-02
Hodgson IanChief Operating Officer · Common Stock, par value $0.0001 per shareSold 847 @ $7,38$6K · 2026-02-17
Moran Sean F.Chief Financial Officer · Common Stock, par value $0.0001 per shareSold 4 701 @ $7,78$37K · 2026-02-13
Cohen YuvalDirector, Chief Executive Officer · Common Stock, par value $0.0001 per shareSold 13 871 @ $7,78$108K · 2026-02-13
Smethurst DominicChief Medical Officer · Common Stock, par value $0.0001 per shareSold 3 285 @ $8,09$27K · 2026-02-03
Hodgson IanChief Operating Officer · Common Stock, par value $0.0001 per shareSold 2 415 @ $8,09$20K · 2026-02-03
Smethurst DominicChief Medical Officer · Common Stock, par value $0.0001 per shareOther 28 365 · 2026-01-14
Moran Sean F.Chief Financial Officer · Common Stock, par value $0.0001 per shareOther 28 082 · 2026-01-14
Cohen YuvalDirector, Chief Executive Officer · Common Stock, par value $0.0001 per shareOther 50 000 · 2026-01-14
Hodgson IanChief Operating Officer · Common Stock, par value $0.0001 per shareOther 28 365 · 2026-01-14
Cormorant Asset Management, LP10% owner · Common StockSold 30 029 @ $11,46$344K · 2025-12-11
Cohen YuvalDirector, Chief Executive Officer · Common Stock, par value $0.0001 per shareOther 8 973 @ $4,26$38K · 2025-10-27
Cohen YuvalDirector, Chief Executive Officer · Common Stock, par value $0.0001 per shareSold 8 973 @ $17,14$154K · 2025-10-27

Short positioning

2.1Mshares short+7.8% vs prior

5.9days to cover

52.9%short of daily vol

3.4Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

CRBPCanonical

Nasdaq · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskHigh

Liquidity riskHigh

Diluted share count is moderately above the basic share count.

Filings reference going-concern or substantial-doubt language.

Source documents mention dilution or offering risk.

Relationship graph

This companySectorPartners

Evidence & claims

From filings & derived data

R&D expense (annual): USD 70.09MUnknown
Net income (annual): USD -78.54MUnknown
Operating income (annual): USD -85.31MUnknown
Operating cash flow (annual): USD -64.49MUnknown
Current liabilities (annual): USD 20.69MUnknown
Shareholders' equity (annual): USD 147.5MUnknown
Total liabilities (annual): USD 20.69MUnknown
Cash & equivalents (annual): USD 28.49MUnknown
EPS (basic) (annual): USD-PER-SHARES -6Unknown
EPS (diluted) (annual): USD-PER-SHARES -6Unknown
Total operating expenses (annual): USD 85.31MUnknown
Capex (annual): USD 7KUnknown
Shares outstanding (annual): 17.61MUnknown
Current assets (annual): USD 166.95MUnknown
Total assets (annual): USD 168.19MUnknown
Net income (annual): USD -40.21MUnknown
Current assets (annual): USD 152.98MUnknown
Cash & equivalents (annual): USD 17.2MUnknown
Operating income (annual): USD -48.72MUnknown
Shares outstanding (annual): 12.18MUnknown
Total operating expenses (annual): USD 48.72MUnknown
Shareholders' equity (annual): USD 142.43MUnknown
Current liabilities (annual): USD 11.82MUnknown
Operating cash flow (annual): USD -41.79MUnknown

Showing 24 of 30 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-08-04 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-07-07 04:39 UTCFILINGMaterial 8-K

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)

2026-06-10 00:00 UTCINSIDER5 insider transactions — 2026-06 · $174k gross

2026-06-10INSIDERAltmeyer Anne sold 2.4k sh Common Stock, par value $0.0001 per share — Director ~$19k

2026-06-10INSIDERJenkins John Kenneth sold 4.8k sh Common Stock, par value $0.0001 per share — Director ~$38k

2026-06-10INSIDERKung Winston sold 2.0k sh Common Stock, par value $0.0001 per share — Director ~$16k

2026-06-03INSIDERSaxena Nishant C bought 9.0k sh Common Stock, par value $0.0001 per share — Chief Business Officer ~$68k

2026-06-02INSIDERSaxena Nishant C bought 4.5k sh Common Stock, par value $0.0001 per share — Chief Business Officer ~$33k

2026-05-26FILING8-K filing →

2026-05-21 00:00 UTCINSIDER14 insider transactions — 2026-05 7 derivative

2026-05-21FILING8-K filing →

2026-05-21INSIDERSaxena Nishant C transacted 58.3k sh Common Stock, par value $0.0001 per share — Chief Business Officer

2026-05-21INSIDERSaxena Nishant C acquired 192.3k sh Stock options (right to buy) — Chief Business Officer

2026-05-19INSIDERJacques Rachelle Suzanne transacted 3.8k sh Common Stock, par value $0.0001 per share — Director

2026-05-19INSIDERKung Winston transacted 3.8k sh Common Stock, par value $0.0001 per share — Director

2026-05-19INSIDERJenkins John Kenneth transacted 3.8k sh Common Stock, par value $0.0001 per share — Director

2026-05-19INSIDERAltmeyer Anne transacted 3.8k sh Common Stock, par value $0.0001 per share — Director

2026-05-19INSIDERBen Yong transacted 3.8k sh Common Stock, par value $0.0001 per share — Director

2026-05-19INSIDERPfeiffenberger Brent transacted 7.5k sh Common Stock, par value $0.0001 per share — Director

2026-05-19INSIDERJenkins John Kenneth acquired 12.3k sh Stock options (right to buy) — Director

2026-05-19INSIDERBen Yong acquired 12.3k sh Stock options (right to buy) — Director

2026-05-19INSIDERPfeiffenberger Brent acquired 24.7k sh Stock options (right to buy) — Director

2026-05-19INSIDERKung Winston acquired 12.3k sh Stock options (right to buy) — Director

2026-05-19INSIDERJacques Rachelle Suzanne acquired 12.3k sh Stock options (right to buy) — Director

2026-05-19INSIDERAltmeyer Anne acquired 12.3k sh Stock options (right to buy) — Director

2026-05-14FILING8-K filing →

2026-05-12FILING10-Q filing →

2026-05-12FILING8-K filing →

2026-04-16FILING8-K filing →

2026-04-14FILING8-K filing →

2026-04-07FILING8-K filing →

2026-04-02FILINGDEF 14A filing →

2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD -23.0M

2026-03-25FILING424B3 filing →

2026-03-09FILING10-K filing →

2026-03-09FILING8-K filing →

2026-03-02 00:00 UTCINSIDER1 insider transaction — 2026-03

2026-03-02INSIDERSmethurst Dominic sold 6.1k sh Common Stock, par value $0.0001 per share — Chief Medical Officer ~$51k

Showing the 40 most recent of 68 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread